VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRLA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRLAIRulya Therapeutics Inc.
$40.59$39M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIRLAFinancials

IRulya Therapeutics Inc. (IRLA) Income Statement

9Y historyFree accessUpdated daily

The company exhibits a complete absence of revenue generation, with quarterly operating losses frequently exceeding $10 million, as seen in the $11.1 million loss reported for 2026Q1.

Income StatementBalance SheetCash FlowRatios

IRLA Income Statement

Annual statement

IRLA Income Statement

IRulya Therapeutics Inc. (IRLA) annual income statement — 9-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Sales/Revenue0000000000
Revenue Growth %----------
Cost of Goods Sold51K142K00000051K45K
COGS % of Revenue----------
Gross Profit-51K-142K000000-51K-45K
Gross Margin %----------
Gross Profit Growth %-------100%-13.33%-
Operating Expenses125.08M50.29M57.28M34.62M52.02M90.32M78.89M39.17M12.12M10.37M
OpEx % of Revenue----------
Selling, General & Admin33.55M15.05M17.58M17.7M26.01M29.52M17.59M8.95M2.03M1.27M
SG&A % of Revenue----------
Research & Development30.76M35.38M18.59M9.45M25.18M60.8M61.31M30.21M10.09M9.1M
R&D % of Revenue----------
Other Operating Expenses1.96M-142K21.11M7.48M825K00000
Operating Income-125.12M-50.43M-57.28M-34.62M-52.02M-90.32M-78.89M-39.17M-12.12M-10.37M
Operating Margin %----------
Operating Income Growth %-11.97%-65.47%33.44%42.41%-14.48%-101.42%-223.19%-16.87%-
EBITDA-124.99M-50.29M-57.1M-34.3M-51.81M-89.97M-78.56M-38.98M-12.07M-10.32M
EBITDA Margin %----------
EBITDA Growth %-159.46%11.93%-66.48%33.8%42.42%-14.53%-101.54%-223%-16.88%-
D&A (Non-Cash Add-back)131K142K186K322K204K344K332K188K51K45K
EBIT-75.95M-80.77M-36.17M-27.14M-51.19M-89.94M-78.89M-39.17M-11.52M-10.37M
Net Interest Income2M1.24M2.93M3.48M500K620K2.04M2.19M-151K0
Interest Income2M1.24M2.93M3.48M1.07M620K2.04M2.19M806K0
Interest Expense0000568K000957K1.64M
Other Income/Expense15.92M-30.34M544K3.04M71K373K2.04M2.19M-357K-1.86M
Pretax Income-109.2M-80.77M-56.74M-31.58M-51.94M-89.94M-76.85M-36.98M-12.48M-12.23M
Pretax Margin %----------
Income Tax-2.42M3.21M87K-197K-284K00000
Effective Tax Rate %2.22%-3.98%-0.15%0.62%0.55%0%0%0%0%0%
Net Income-106.78M-83.98M-56.83M-31.39M-51.66M-89.94M-76.85M-36.98M-12.48M-12.23M
Net Margin %----------
Net Income Growth %-87.4%-47.78%-81.07%39.25%42.56%-17.04%-107.81%-196.41%-1.97%-
Net Income (Continuing)-106.78M-83.98M-56.83M-31.39M-51.66M-89.94M-76.85M-36.98M-12.48M-12.23M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)-8.89-336.00-262.00-168.00-308.00-606.00-526.00-386.00-116.00-114.00
EPS Growth %91.23%-28.24%-55.95%45.45%49.17%-15.21%-36.27%-232.76%-1.75%-
EPS (Basic)--336.00-262.00-168.00-308.00-606.00-526.00-386.00-116.00-114.00
Diluted Shares Outstanding12M250.49K216.31K186.19K167.48K148.59K145.88K95.16K107.76K107.76K
Basic Shares Outstanding12M250.49K216.31K186.19K167.48K148.59K145.88K95.16K107.76K107.76K
Dividend Payout Ratio----------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Clinical Development Drives Expense Volatility

As reported in recent financial statements, QNCX maintains a high-burn cost structure, with R&D expenses fluctuating between $3.4 million and $12.6 million per quarter, reflecting the intensive capital requirements of advancing the NOV004 clinical program through necessary regulatory and trial milestones.

The company's cost structure is almost entirely comprised of R&D and SG&A, as it lacks commercial revenue to offset these operational outlays. The variability in R&D spending suggests that clinical trial execution is not yet a predictable, steady-state process, which complicates long-term cash flow forecasting for investors.

Non-Operating Items Distort Net Results

Based on the 2026Q1 income statement, the company reported a net income of $35.9 million, a figure that appears disconnected from operational reality and likely stems from non-operating accounting adjustments rather than core business performance or sustainable profitability.

Investors should exercise caution when interpreting these bottom-line figures, as they do not reflect the underlying clinical-stage business model. The presence of such anomalies suggests that the net income line is currently an unreliable indicator of the company's true financial health or its ability to generate future shareholder value.

Operating Leverage Remains Entirely Absent

According to historical income statement data, QNCX consistently records negative operating margins, with quarterly operating losses frequently exceeding $10 million, indicating that the firm has yet to achieve the scale necessary to leverage its fixed SG&A and R&D infrastructure.

The lack of revenue generation means that every dollar spent on operations directly erodes the company's limited cash reserves. Without a commercial product to provide operating leverage, the firm remains entirely dependent on external financing to sustain its current research-heavy cost structure.

Liquidity Constraints Threaten Operational Continuity

With a reported cash balance of approximately $5.8 million, the company faces a precarious financial position that, based on historical quarterly burn rates, suggests an urgent requirement for additional capital to avoid a potential cessation of clinical activities in the near term.

The current cash position appears insufficient to support the long-term development of the BTP platform without significant dilution to existing shareholders. This liquidity risk warrants close monitoring, as any delay in securing funding could force the company into a distressed strategic transaction or a pivot that further compromises its long-term competitive positioning.

IRLA — Frequently Asked Questions

Quick answers to the most common questions about buying IRLA stock.

What was IRulya Therapeutics Inc.'s (IRLA) revenue in 2025?

For fiscal year 2025, IRulya Therapeutics Inc. (IRLA) reported total revenue of $0.0M.

Is IRulya Therapeutics Inc. (IRLA) profitable?

IRulya Therapeutics Inc. (IRLA) reported a net loss of $84.0M for the fiscal year ending 2025.